← ANALYST RATINGS · TIPRANKS
908 Devices (MASS): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy0 Hold0 Sell
Ratings of 5 analysts in the last 3 months12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $13.17, the highest $14.00, the lowest $12.00. The average is +16.9% from the last price of $11.26.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Medical - SpecialtiesxAI Grok-4 | TipRanks - xAI | $12.50 → $12.00−4.0% | Hold | +6.6% | Reiterated | 17.10.26on TipRanks 06:07 | — | |
| AI DeepSeek Medical - SpecialtiesDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $12.50 → $12.00−4.0% | Hold | +6.6% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI OpenAI Medical - SpecialtiesOpenAI 5.2 | TipRanks - OpenAI | $13.00 → $12.00−7.7% | Hold | +6.6% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI Anthropic Medical - SpecialtiesAnthropic Opus-4.6 | TipRanks - Anthropic | $12.00 → $11.00−8.3% | Hold | −2.3% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI Google Medical - SpecialtiesGemini 3.1Pro | TipRanks - Google | $13.00 → $12.50−3.8% | Hold | +11.0% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI PerPlexity Medical - SpecialtiesPerPlexity SonarPro | TipRanks - PerPlexity | $12.50 → $12.00−4.0% | Hold | +6.6% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| Max Masucci★★★★★★★★★★#2606 · hits 42% · avg +8.5% | Roth MKM | $13.00 → $14.00+7.7% | Buy | +24.3% | Reiterated | 22.09.26on TipRanks 09:10 | +2.8%next day −1.4% · 5 days +7.2% | ↗ |
| Austin Moeller★★★★★★★★★★#2724 · hits 42% · avg +6.3% | Canaccord Genuity | $13.50 | Buy | +19.9% | Initiated | 11.09.26on TipRanks Sep 10 07:08 | −2.9%next day +1.0% · 5 days +16.8% | ↗ |
| Daniel Arias★★★★★★★★★★#1848 · hits 50% · avg +8.0% | Stifel Nicolaus | $10.00 → $12.00+20.0% | Buy | +6.6% | Reiterated | 12.08.26on TipRanks 07:10 | −0.2%next day +0.2% · 5 days +2.6% | ↗ |
| Brendan Smith★★★★★★★★★★#458 · hits 56% · avg +27.3% | TD Cowen | — | Buy | — | Reiterated | 11.08.26on TipRanks Aug 12 01:20 | +14.1%next day −0.2% · 5 days +1.1% | ↗ |
| Matt Larew★★★★★★★★★★#816 · hits 63% · avg +19.3% | William Blair | — | Buy | — | Reiterated | 11.08.26on TipRanks 10:37 | +14.1%next day −0.2% · 5 days +1.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering 908 Devices
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $13.17 at a price of $12.34 (+6.7%); now: $13.17 at $11.26 (+16.9%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 6 | 3 | 4 | 5 | 7 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 16.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.15 (from $-0.28 to $-0.11). Last quarter: $-0.32.
Sales
Next quarter’s sales estimate — $18M (from $17M to $19M). Last quarter: $16M.
Best top-analyst consensus in the sector · Healthcare
About 908 Devices
- CEO: Kevin J. Knopp
- Employees: 172
- 44 3rd Avenue, Burlington, MA, 01803, US
- www.908devices.com
908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. The company’s products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; XplorIR, a handheld device that uses FTIR spectroscopy to identify, quantify, and track gases and vapors; ThreatID, a portable FTIR device that rapidly detects and identifies approximately 28,000 unknown gas, vapor, powder, and liquid chemical hazards; ProtectIR, a handheld FTIR device that can identify approximately 23,000 solid and liquid chemical hazards; and VipIR, a handheld 3-in-1 analyzer that integrates FTIR, Raman spectroscopy, and smart spectral processing (SSP), a proprietary algorithm, to provide a single result from just one sample. It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of Americas. The company was incorporated in 2012 and is headquartered in Burlington, Massachusetts.
Data from the stock’s TipRanks forecast page, read 53 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗